Xeris (XERS) Ships One Millionth Gvoke Unit

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Xeris has shipped more than one million units of Gvoke® – the company’s ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children with diabetes ages 2 years and above.

“We are proud to celebrate this major milestone of having shipped over one million units of Gvoke since its launch,” said Paul R. Edick, Xeris’ Chairman and CEO. “However, far too many people with diabetes are still left without protection against a potentially life-threatening severe low blood sugar event. Based on recently updated guidelines by the American Diabetes Association1 and others, we estimate that approximately 15 million people2 with diabetes are at increased risk of low blood sugar, a primary risk factor being on insulin, and should be carrying a ready-to-use glucagon, like Gvoke HypoPen®,” Mr. Edick continued, “We will continue to work tirelessly towards our mission of protecting as many of the 15 million as possible and call on the medical community to take responsibility to make these new standards of care your standards of practice.”

You May Also Be Interested In

• Abbott settles preterm formula NEC lawsuits for $670 million
• Virtus Investment Partners names Jack Boyce to its board
• Trustar Bank to acquire Forbright Bank branches for $750M in deposits